FCRL1

Across TCGA pan-cancer cohorts, FCRL1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FCRL1 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher FCRL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FCRL1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and SKCM show a favorable association.

ESCA, LGG, and BRCA are the cancer types where FCRL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.322	0.710	.002	21	view →
LGG	DFS	Median	All	0.172	0.845	<.001	6	view →
BRCA	DFS	Median	III,IV	0.201	0.796	.001	6	view →
PRAD	DFS	Median	All	0.174	0.888	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	All	1.000	0.663	.031	4	view →
SKCM	OS	Median	III,IV	1.000	0.781	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FCRL1–ESCA (OS)

Open the ESCA breakdown →